For patients with acute myeloid and lymphoblastic leukaemia (AML/ALL) lacking a matched
sibling or unrelated donor, haploidentical stem cell transplantation (HAPLO-SCT) is …

With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched
related donor hematopoietic cell transplantation (HCT) are now approaching those of …

Simple Summary Human leukocyte antigen (HLA)–haploidentical haematopoietic stem cell
transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCY) for …

Background Both mismatched unrelated donor (MMUD) and haploidentical (haplo)
transplantation are valid options in patients with high‐risk acute lymphoblastic leukemia …

One of the consistent features in development of hematopoietic stem cell transplant (HCT)
for Acute Lymphoblastic Leukemia (ALL) is the rapidity with which discoveries in the …

Adults compose nearly half of all patients diagnosed with acute lymphoblastic leukemia
(ALL) and historically have had poor survival compared with pediatric patients. Recently …

Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT), including
human leukocyte antigen-matched sibling donor transplantation and alternative donor …

Background Although the clinical outcomes of patients with TP53‐mutated acute myeloid
leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare …

Endothelial dysfunction and damage play important roles in the pathophysiology of graft
versus host disease (GvHD) and hepatic venoocclusive disease/sinusoidal obstruction …

Allogeneic hematopoietic cell transplantation (HCT) remains an important treatment for
adults with acute lymphoblastic leukemia (ALL). We hypothesized that advances in ALL and …